Clinical Trials Logo

Nervous System Diseases clinical trials

View clinical trials related to Nervous System Diseases.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05961163 Terminated - Stroke Clinical Trials

Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures: an Observational Study

CLIMATE
Start date: July 24, 2023
Phase:
Study type: Observational

The CLIMATE Observational Study examines to what extent chronically ill patients experience adverse health effects because of heat and whether the patients' specific efforts, somatosensory amplification, self-efficacy, health literacy and commitment to the GP, degree of urbanisation of the patients' administration district and characteristics of the patients' neighborhood are associated with these effects.

NCT ID: NCT05622786 Terminated - Clinical trials for Traumatic Brain Injury

Effect of High-Intensity Gait Training Using a Treadmill on Locomotion Recovery in Traumatic Brain Injury Patients

Start date: October 7, 2022
Phase: N/A
Study type: Interventional

The project will consist of subjects who have suffered Traumatic Brain Injury (TBI) and who are able to ambulate on treadmill with or without a harness system. This will be a 4-week controlled study consisting of two groups of TBI patients, high-intensity intervention group and low-intensity control group. Both groups will receive physical therapy treatment 3 times per week for 1 hour. The intervention group will undergo 30-minute sessions of high-intensity walking on a treadmill with an overhead harness attached for safety. In addition, they will also get up to 30-minutes of low-intensity physical therapy in order to receive 1 hour of treatment time. The control group will undergo only low-intensity physical therapy activities for 1-hour. Low-intensity physical therapy will include strength exercises, stretches, balance, and low-intensity gait training. All participants in both groups will complete these outcome measures on the first day of the study, after 2 weeks of participation, and again at the end of 4 weeks or on their last day before discharge from Carilion's services. Later on, all participants in both groups will be followed up to complete the same set of outcome measures at the end of 1 month since completion of the protocol. This follow up session will take up to 45 minutes to complete.

NCT ID: NCT05089682 Terminated - Parkinson Disease Clinical Trials

Manipulating and Optimizing Brain Rhythms for Enhancement of Sleep

Start date: June 22, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to investigate whether researchers can improve sleep quality in patients with deep brain stimulators by delivering targeted stimulation patterns during specific stages of sleep.

NCT ID: NCT05019105 Terminated - Clinical trials for Central Nervous System Diseases

Phase 1 ALKS 1140 in Healthy Adults

Start date: October 13, 2021
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of ALKS 1140 in healthy adult subjects

NCT ID: NCT04912856 Terminated - Epilepsy Clinical Trials

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

EPIK-OLE
Start date: August 17, 2021
Phase: Phase 3
Study type: Interventional

To assess the long-term safety and tolerability of XEN496 in pediatric subjects with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) who had participated in the primary study (XPF-009-301).

NCT ID: NCT04639310 Terminated - Epilepsy Clinical Trials

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

EPIK
Start date: March 29, 2021
Phase: Phase 3
Study type: Interventional

To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).

NCT ID: NCT03887533 Terminated - Clinical trials for Niemann-Pick Disease, Type C1

Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1

Start date: January 6, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Background: For people who have Niemann-Pick disease, type C1 (NPC1), cholesterol and other fats have trouble moving out of liver and other tissue cells. This makes the cells sick. Researchers want to find out if a drug called VTS-270 can help. Objective: To test if VTS-270 is safe and effective in treating chronic liver disease associated with NPC1. Eligibility: People ages 3-60 with NPC1 Design: Participants may be screened by phone or under another protocol. Participants will have visits once a month for 12 months. If they have intrathecal injections, the study may last 15 months or more. The first visit will last about 5 days. Others will last 2-3 days. Participants will get VTS-270 injected into a vein at each visit. They can also choose to have intrathecal injections. These are like spinal taps. Some visits will also include: Physical exam Urine tests Blood tests. A small tube or needle will be inserted into the participants vein to collect blood. The small tube will also be used to give the VTS-270. Hearing tests: For one test, participants will have electrodes taped to their head. These will record brain waves. Breathing tests Ultrasound of abdomen: Sounds waves will take pictures of the participant s body. Chest x-ray: This is a picture of the lungs.

NCT ID: NCT03762902 Terminated - Migraine Disorders Clinical Trials

Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the Smartphone

Migraine
Start date: April 30, 2019
Phase:
Study type: Observational

This study is conducted at the Henry Ford Health System with Lifegraph's behavioral monitoring technology, to examine the relation between migraine attacks and behavioral and environmental changes as detected from the smartphone sensors. The investigators hypothesize that Lifegraph's technology can predict the occurrence of migraine attacks with high precision.

NCT ID: NCT03737331 Terminated - Clinical trials for Gait Disorders, Neurologic

Variable Visual Stimulus as a Novel Approach for Gait Rehabilitation

VISNA
Start date: November 9, 2018
Phase: N/A
Study type: Interventional

Deterioration in walking performance as a result of disease or simply as a result of aging is a serious threat to independence in older adults. In this project, the investigators propose an innovative visual stimulus, based on advanced mathematical and biological theories, with which older adults can walk in time to improve their walking. The investigators' goal is to apply this simple, cost-effective, and novel gait rehabilitation therapy across all populations who have difficulties walking, e.g. stroke patients, fallers or those who undergo joint replacement.

NCT ID: NCT03731078 Terminated - Clinical trials for Functional Neurological Disorder

Pilot Study of Cognitive Behavioral Therapy-Informed Physical Therapy Intervention in Functional Neurological Disorders

Start date: March 8, 2019
Phase:
Study type: Observational

Functional Neurological Disorder (FND/ Conversion Disorder) is a highly prevalent and disabling neuropsychiatric condition. Motor FND symptoms include Functional Movement Disorders (FMD) and Functional Weakness and Psychogenic Nonepileptic Seizures (PNES).Though patients with FND present with a wide variety of symptoms, FMD, PNES, and functional weakness may be viewed as overlapping conditions lying along a phenotypic spectrum for a single disorder. Patients with FND frequently present with psychiatric symptoms, including depression, anxiety, Borderline Personality Disorder, and Post-Traumatic Stress Disorder, alongside their physical symptoms. To treat these symptoms, patients with FND are frequently enrolled in physical therapy and cognitive behavioral therapy, which are considered usual care for FND at our center. Developing a further understanding of treatment outcome, including biomarkers of clinical improvement and psychometric factors associated with treatment response, could inform future interventions and better tailor treatments to patients with specific FND symptom profiles. We hypothesize that treatment response will be associated with structural and functional alterations in salience network regions and that more adaptive neuropsychiatric profiles at baseline will predict a positive treatment outcome.